DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the JEENA SIKHO LIFECARE LTD (JSLL) share price today?

JEENA SIKHO LIFECARE LTD (JSLL) is trading at ₹565.65 on the NSE, down 2.15% on the day. Source: DocStoX.

What is the PE ratio of JEENA SIKHO LIFECARE LTD?

JEENA SIKHO LIFECARE LTD has a price-to-earnings (PE) ratio of 77.5 in the Consumer Services sector.

What is the market capitalisation of JEENA SIKHO LIFECARE LTD?

JEENA SIKHO LIFECARE LTD has a market capitalisation of approximately ₹7,051 crore.

JEENA SIKHO LIFECARE LTD

JSLL·NSE·Consumer Services

₹565.65▼ -12.45 (-2.15%)

Consumer Services · Pharmaceuticals

High-quality returns — 27% on equity

Day₹563.00

₹581.35

52W₹492

₹85021%

Open

₹579.80

High

₹581.35

Low

₹563.00

Prev Close

₹578.10

Volume

2.44L

VWAP

₹567.16

Snapshot

Key fundamentals

Market Cap

₹7,051 Cr

P/E Ratio

77.49Expensive

P/B Ratio

15.25

EPS

₹7.30

Book Value

₹37.58

ROE

26.65%Strong

ROCE

50.00%Efficient

Dividend Yield

0.19%

Debt / Equity

0.27Low

Face Value

₹2.00

52W High

₹849.50

52W Low

₹492.00

Sector

Consumer Services

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹72

▼ 87.3%downside

Trading at ₹566 — 87% above our estimate

BearFair valueBull

₹61₹72₹83

/100

Business quality — Solid

Growth 0Profitability 98Efficiency 58Valuation 43

Plain English

Our view

High-quality returns — 27% on equity
Low debt relative to equity
Revenue has been shrinking

Strengths

Low debt relative to equity
Strong returns on equity (27%)
Capital is working hard (ROCE 50%)
Promoters hold a controlling stake

Risks

Revenue has been shrinking
Expensive — trades at 77× earnings

How we got there

Fair value methods

Residual income

27% ROE fading to 12% over ~10 yrs, on ₹38 book

₹70

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹79

Analyst target

No analyst coverage

—

Blended fair value₹72

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Strong returns on equity (27%)
Capital is working hard (ROCE 50%)
Promoters hold a controlling stake

Bear case

Revenue has been shrinking
Expensive — trades at 77× earnings

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

77.5Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

26.6%Strong

Above 15% is considered healthy for Indian equities

ROCE

50.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.27Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹7,051 Cr

P/B

15.25

EPS

₹7.30

Div Yield

0.19%

What changed

Recent changes

Foreign investors-0.1% stake last quarter
Domestic institutions+0.4% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 77.5×

Growth

Strong

+58% rev CAGR

Profitability

Excellent

26.6% ROE

Financial health

Rock solid

D/E 0.27

Momentum

N/A

No technicals

Today

Trading activity

Delivery %51.8%

Turnover₹1383.66L Cr

Trades9,690

VWAP₹567.16

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+57.8%

+42.6%

10Y

—

Profit

+86.9%

+85.9%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is expected to give good quarter
Company has delivered good profit growth of 84.5% CAGR over last 5 years
Company has a good return on equity (ROE) track record: 3 Years ROE 49.6%
Company has been maintaining a healthy dividend payout of 19.1%
Debtor days have improved from 51.4 to 31.8 days.

Watch-outs

Cons

Stock is trading at 15.8 times its book value

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Foreign investors sold 0.14 pts; domestic institutions added 0.35 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

64%

Promoter

Promoters

63.6%0.00

Public

29.8%-0.20

FII / FPI

6.2%-0.14

DII

0.5%+0.35

Total shareholders

25,905+3,724 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter63.62%

FII6.17%

DII0.46%

Public29.77%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Jeena Sikho Lifecare is one of the leading ayurvedic healthcare system providers in India. The company is providing healthcare services for the last ten years.